Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL1 | P55085 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.51 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | LDHA | P00338 | 1/20 | 0.49 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22036296 | 0.86 | F2RL1 (0.64) | F2RL1ALDH1A1POLBFFAR1NFKB1 | |
| SCHEMBL20221730 | 0.86 | F2RL1 (0.64) | F2RL1ALDH1A1POLBFFAR1NFKB1 | |
| SCHEMBL7329940 | 0.86 | F2RL1 (0.85) | F2RL1ALDH1A1POLBFFAR1NFKB1 | |
| SCHEMBL9404116 | 0.82 | F2RL1 (1.00) | F2RL1ALDH1A1POLBFFAR1NFKB1 | |
| SCHEMBL105364 | 0.81 | TRPV1 (0.59) | F2RL1ALDH1A1POLBNFKB1NFKB2 | |
| SCHEMBL3994134 | 0.81 | F2RL1 (0.77) | F2RL1ALDH1A1POLBFFAR1NFKB1 | |
| SCHEMBL29249334 | 0.81 | TRPA1 (0.53) | NFKB1LMNAALOX5 | |
| SCHEMBL24799947 | 0.81 | F2RL1 (0.66) | F2RL1ALDH1A1POLBFFAR1NFKB1 | |
| SCHEMBL20610764 | 0.81 | F2RL1 (0.66) | F2RL1ALDH1A1POLBFFAR1NFKB1 | |
| SCHEMBL2468019 | 0.80 | F2RL1 (0.60) | F2RL1ALDH1A1POLBFFAR1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128195-A1 | SYNTHESIS OF HALICHONDRINS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-04-27 | — | — | US | disclosed |
| US-7473790-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | PFIZER INC. (US) | 2009-01-06 | — | — | US | disclosed |
| US-7473790-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | PFIZER INC. (US) | 2009-01-06 | — | — | US | disclosed |
| US-7473790-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | PFIZER INC. (US) | 2009-01-06 | — | — | US | disclosed |
| US-7148226-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20060189681-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
| EP-1597246-A2 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20050176701-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2005-08-11 | — | — | US | disclosed |
| WO-2004074270-A2 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189681-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | RNASE1, RNASEH1, NSUN3 | F2RL1 1698/4885ALDH1A1 322/4885POLB 159/4885 |
| US-20230128195-A1 | SYNTHESIS OF HALICHONDRINS | H1-3, NISCH, HDAC11 | F2RL1 4305/4885ALDH1A1 1842/4885POLB 1606/4885 |
| US-20050176701-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | RNASE1, RNASEH1, NSUN3 | F2RL1 1698/4885ALDH1A1 322/4885POLB 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.